Scar News and Research

RSS

New computerized catheter makes surgical treatment of atrial fibrillation faster, cheaper and more effective

Atrial fibrillation is a heart disorder that affects more than two million Americans, and is considered a key contributor to blood clots and stroke. Now researchers from North Carolina State University are developing a new computerized catheter that could make the surgical treatment of atrial fibrillation faster, cheaper and more effective - while significantly decreasing radiation exposure related to the treatment.

16 Sep 2010

Capstone Therapeutics reaches overall progress in AZX100 Phase 2a clinical trials for keloid scarring

Capstone Therapeutics announced today that participating subjects have reached the planned twelve-month timepoint in the first of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. Data analysis for these subjects is underway. Per protocol and the original clinical development plan, results of the two keloid scarring trials will be pooled for analytical purposes and are scheduled for release during 4Q2010.

14 Sep 2010

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

Bioheart, Inc., The mission of the Cell Therapy Foundation is to improve public health through the support of effective adult stem cell research and education. The Foundation aims to promote basic and applied knowledge, processes and cell therapies.

31 Aug 2010

LESSON I trial provides evidence of benefits of everolimus-eluting stent over sirolimus-eluting stent

Results from the LESSON I trial presented today provide preliminary evidence for the therapeutic benefit of the newer generation everolimus-eluting stent over the previous gold standard, the early generation sirolimus-eluting stent. Moreover, LESSON I provides evidence that the formation of blood clots (stent thrombosis) - the principal shortcoming of early generation drug-eluting stents - may be diminished with the newer generation everolimus-eluting stent.

31 Aug 2010

First ROSE procedures with USGI Medical's Incisionless Operating Platform performed in Europe

USGI Medical, Inc., the Incisionless Surgery Company, announced that a surgeon in the U.K. successfully completed Europe's first two scar-free stomach surgery repairs using the company's Incisionless Operating Platform™ (IOP). Elemental Healthcare Ltd. distributes the IOP in the U.K. market.

30 Aug 2010

'Pre-vascularization' of device prior to implantation sustains circulation and suppresses scar formation

By creating a unique system of blood vessels that is engineered to interact with the tissue surrounding an implanted device, the longevity and function of these devices may be better preserved, according to a study led by researchers in the University of Louisville/ Jewish Hospital's Cardiovascular Innovation Institute (CII).

24 Aug 2010

Fluid dynamics and mechanics to simulate stent design and coating

Suncica "Sunny" Canic was good at math in school, so that's what she pursued as a career. But she always liked medicine, too. When she moved to Houston, Texas, and met some cardiologists at a party, she started talking with them about what they do-and knew she could help them.

23 Aug 2010

University of Maryland researchers link 3-D CT scans to standard ablation techniques

Researchers at the University of Maryland School of Medicine in Baltimore have developed a novel 3-D imaging approach that may improve the accuracy of treatment for ventricular tachycardia, a potentially life-threatening heart rhythm disorder that causes the heart to beat too fast. The new approach couples CT images with conventional ablation techniques to eliminate erratic electrical circuits in the heart that produce arrhythmias.

19 Aug 2010

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication.

17 Aug 2010

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

YM BioSciences Inc., announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory.

10 Aug 2010

New scaffold supports growth, integration of stem cell-derived cardiac muscle cells

These days people usually don't die from a heart attack. But the damage to heart muscle is irreversible, and most patients eventually succumb to congestive heart failure, the most common cause of death in developed countries.Stem cells now offer hope for achieving what the body can't do: mending broken hearts. Engineers and physicians at the University of Washington have built a scaffold that supports the growth and integration of stem cell-derived cardiac muscle cells. A description of the scaffold, which supports the growth of cardiac cells in the lab and encourages blood vessel growth in living animals, is published this week in the Proceedings of the National Academy of Sciences.

10 Aug 2010

Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a clinical study report for its Phase II/III study of azficel-T for the treatment of moderate to severe acne scars to the U.S. Food & Drug Administration (FDA).

9 Aug 2010

BioVentrix announces First-in-Man milestone for PliCath heart failure system

BioVentrix, developer of the PliCath HF™ System for use in Epicardial Catheter-based Ventricular Reconstruction (ECVR), today announced achievement of its First-in-Man milestone, performed on a 52-year-old male heart failure patient in Krakow, Poland. The PliCath HF System is designed to treat heart failure (HF) by reducing the enlarged Left Ventricle (LV) through an anchoring system that is delivered across the cardiac chambers with the use of a catheter.

9 Aug 2010

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

YM BioSciences Inc., announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients.

5 Aug 2010

Excaliard reports positive results from EXC 001 Phase 2 clinical trial for reducing scar severity

Excaliard Pharmaceuticals, Inc., today announced positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.

4 Aug 2010

Combat veterans face challenges at high rates than non-veterans: Research

From the many images sent home from foreign battlefields over the last several decades, Americans have viewed the plight of their country's combat-weary veterans as stark and often iconic scenes that seem somehow frozen in time. But recent research at Washington State University suggests that, for many U.S. veterans, combat is a defining experience that often sets the trajectory of the balance of their lives.

3 Aug 2010

Studies that compare treatment options for carotid artery disease provide no clear answer, physician reports

A review of scientific studies that compares two treatments for preventing strokes due carotid artery disease provides no clear answer on which treatment is better, a UT Southwestern Medical Center physician reports in an editorial in today's issue of the Archives of Internal Medicine.

27 Jul 2010

DEKA Medical announces availability of new SmartXide DOT HP Fractional CO2 laser

DEKA Medical announced today the immediate availability of the High-Powered SmartXide DOT. The new SmartXide DOT HP Fractional CO2 laser, with average power of 50W, can attain irradiance of up to 250W of power with each pulse. This makes the new SmartXide DOT HP the most powerful superpulse CO2 laser available to aesthetic physicians.

19 Jul 2010

UCI first medical center on West Coast to perform robotic thyroidectomies

UC Irvine Healthcare is the first medical center on the West Coast and the only one in California to perform robotic thyroidectomies, a procedure that removes the diseased gland without leaving a visible scar on the neck. Dr. Jason Kim, associate clinical professor of otolaryngology and a head and neck cancer specialist, has performed robotic-assisted surgery using the daVinci Surgical System on three patients with thyroid tumors.

16 Jul 2010

Top treatments and tests for hair loss

August is National Hair Loss Awareness Month and it's an important time for men and women to talk to their doctors about the newest tests and treatments available to help them. Over 100 million Americans are affected - including 60 million men and 40 million women.

15 Jul 2010